Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 3/20 | 0.54 |
| ▸ | F10 | P00742 | 10/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | APEX1 | P27695 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5141746 | 0.98 | DPP4 (0.53) | DPP4F10ALDH1A1HTTCYP3A4 | |
| SCHEMBL6030098 | 0.98 | DPP4 (0.53) | DPP4F10ALDH1A1HTTCYP3A4 | |
| SCHEMBL5144938 | 0.98 | DPP4 (0.53) | DPP4F10ALDH1A1HTTCYP3A4 | |
| SCHEMBL6031441 | 0.98 | DPP4 (0.53) | DPP4F10ALDH1A1HTTCYP3A4 | |
| SCHEMBL24323789 | 0.88 | DPP4 (0.51) | DPP4F10CYP3A4TSHRTDP1 | |
| SCHEMBL24322499 | 0.87 | DPP4 (0.50) | DPP4F10GAA | |
| SCHEMBL24322545 | 0.87 | DPP4 (0.50) | DPP4F10CYP3A4TSHRTDP1 | |
| SCHEMBL4756703 | 0.87 | DPP4 (0.50) | DPP4F10GAA | |
| SCHEMBL3172775 | 0.87 | DPP4 (0.50) | DPP4F10GAA | |
| Hydrochloric Acid SCHEMBL3166507 | 0.85 | DPP4 (0.49) | DPP4F10GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220122691-A1 | HtrA Inhibitors and CagA Inhibitors and Use Thereof | Psomagen Inc. (US) | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220122691-A1 | HtrA Inhibitors and CagA Inhibitors and Use Thereof | HTRA1, GIPR, HPN | DPP4 532/4885F10 1781/4885ALDH1A1 4556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.